Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.49 |
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094230 | 0.88 | HDAC1 (0.48) | HDAC1KDM1AHDAC2MAOACYP3A4 | |
| SCHEMBL3104800 | 0.85 | KDM1A (0.51) | HDAC1KDM1AHDAC2MAOAHDAC4 | |
| SCHEMBL3099070 | 0.85 | HDAC1 (0.52) | HDAC1KDM1AHDAC2MAOAHDAC4 | |
| SCHEMBL17483898 | 0.81 | HDAC1 (0.67) | HDAC1KDM1AHDAC2MAOAHDAC4 | |
| SCHEMBL3099615 | 0.80 | HDAC1 (0.49) | HDAC1KDM1AHDAC2MAOAHDAC4 | |
| SCHEMBL17483901 | 0.80 | HDAC1 (0.57) | HDAC1KDM1AHDAC2MAOAHDAC4 | |
| SCHEMBL17483899 | 0.79 | HDAC1 (0.55) | HDAC1KDM1AHDAC2MAOAHDAC4 | |
| SCHEMBL3098218 | 0.77 | HDAC1 (0.47) | HDAC1KDM1AHDAC2MAOACYP3A4 | |
| SCHEMBL3098228 | 0.77 | HDAC1 (0.47) | HDAC1KDM1AHDAC2MAOACYP3A4 | |
| SCHEMBL3098448 | 0.77 | HDAC1 (0.44) | HDAC1KDM1AHDAC2MAOACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795315-B2 | N-(2-amino-phenyl)-amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090203681-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203681-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | MKI67, API5, BAD | HDAC1 815/4885KDM1A 4012/4885HDAC2 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.